A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Oral naltrexone is currently used as part of a treatment regimen for alcohol‐dependent patients, but its clinical utility is hampered by poor patient adherence. A long‐acting injectable naltrexone formulation (Vivitrex®) was designed to facilitate patient adherence by providing an extended duration of therapeutic naltrexone over 1 month, thereby eliminating the need for daily dosing. Methods: A multicenter, randomized, double‐blind, placebo‐controlled pilot study was conducted to evaluate the safety and tolerability of intramuscular repeat dose administration of this extended‐release naltrexone formulation in DSM‐IV alcohol‐dependent patients. Thirty patients were randomized to treatment with injectable naltrexone (400 mg; n= 25) or a matching placebo injection (n= 5) and were dosed once every 28 days over 4 months. Psychosocial treatment was offered to patients in both treatment groups. Outcome measures related to drinking activity and trough plasma concentrations of naltrexone and its primary metabolite, 6‐β‐naltrexol, were evaluated. Results: Injectable naltrexone was generally safe and well tolerated. Reported adverse events were mild to moderate and resolved without intervention; only two patients discontinued due to adverse events. The most common adverse events (nausea and headache) occurred at a similar rate for patients in both treatment groups. Pharmacokinetic analysis confirmed that therapeutic levels of naltrexone were delivered throughout the four 1‐month treatment cycles. Conclusions: The results of this pilot study provide the basis and methods for a larger, more definitive trial to determine the utility of this long‐acting injectable naltrexone formulation in the treatment of alcohol‐dependent patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Self-citationNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255 · cited 1×
“Although psychosocial and behavioral therapies help many alcoholdependent persons to reduce alcohol consumption and maintain abstinence, 40–70% of patients who achieve abstinence from alcohol after detoxification or psychosocial or behavioral treatment resume drinking within 1 year of such treatment (Swift, 1999).”
Background
Cited by
Babor, T. F., McRee, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007) · Substance Abuse · doi:10.1300/j465v28n03_03 · Cited by 1,100
“In addition, the long acting, injectable form of naltrexone that is now available may enhance its use in primary care settings (73).”
BackgroundOpioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Self-citationUpdate on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Self-citationHulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135
Metadata
- Authors
- Johnson, B. A., Ait‐Daoud, N., Aubin, H., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., & Ehrich, E.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 28
- Issue
- 9
- Pages
- 1356-1361
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2147784083
- Cited by
- 82
- References
- 5
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence. https://app.cochat.ai/papers/10.1097/01.alc.0000139823.30096.52
- The paper
- Johnson, B. A., Ait‐Daoud, N., Aubin, H., van den Brink, W., Guzzetta, R., Loewy, J., Silverman, B., & Ehrich, E. (2004). A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1097/01.alc.0000139823.30096.52
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.